MONTREAL , Aug. 8, 2022 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), announced today that Health Canada has accepted its New Drug Submission (NDS) for cenobamate tablets as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. A decision from Health Canada as to whether cenobamate tablets can be marketed and sold in Canada under this NDS is expected mid-2023.
"This is an important step in our journey to address the unmet needs of adult patients diagnosed with partial-onset seizures," said Livio Di Francesco , Vice President and General Manager of Paladin. "Paladin Labs is committed to working collaboratively with regulatory, pricing and reimbursement authorities in order to provide cenobamate to appropriate patients as quickly as possible."
The regulatory submission includes efficacy information from two pivotal studies (C013 and C017)1,2, which enrolled a total of 658 patients. The evaluation of safety was conducted over the course of the two pivotal studies, and their respective open-label extensions, and is complemented by a long-term open-label Phase III safety study (C021)3, also presented in the regulatory submission. A total of 1,944 patients with epilepsy have been treated with cenobamate in the clinical development program.
Endo Ventures Limited, a subsidiary of Endo, and SK Biopharmaceuticals signed a licensing agreement in December 2021 granting Endo Ventures Limited the exclusive right to commercialize cenobamate in Canada . Under the terms of this agreement, Paladin Labs is responsible for all commercial activities in Canada related to cenobamate.
About Cenobamate Cenobamate is a novel small molecule with a dual mechanism of action under investigation for treating seizures.4,5,6 Cenobamate, at clinically relevant concentrations, acts both as a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel and inhibits voltage-gated sodium currents.2,3 Long-term data of cenobamate has been studied in the open-label extensions of the double-blind placebo control trials as well as the open-label safety study in adults with uncontrolled partial-onset seizures. Additionally, cenobamate is being assessed in an ongoing randomized, double-blind, placebo-controlled trial evaluating its safety and efficacy as adjunctive therapy in patients with primary generalized tonic-clonic seizures (NCT03678753).7
Cenobamate was discovered by SK Biopharmaceuticals and SK life science, and is an anti-seizure medication for the adjunctive or monotherapy treatment of partial-onset seizures in adults (also known as focal-onset seizures). In November 2019 , the U.S. Food and Drug Administration approved cenobamate tablets, marketed under the trademark XCOPRI® (cenobamate tablets) CV in the U.S., for such treatment. In March 2021 , the European Commission granted marketing authorization for cenobamate tablets, marketed under the trademark ONTOZRY® in Europe , for such treatment.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI® (cenobamate tablets) CV can be found on www.xcopri.com.
About Endo and Paladin Labs Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.
Paladin Labs Inc., headquartered in Montreal, Canada , is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing, medical and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo International plc. For more information visit: www.endo.com or www.paladin-labs.com.
1. https://www.clinicaltrials.gov/ct2/show/NCT01397968
2. https://www.clinicaltrials.gov/ct2/show/NCT01866111
3. https://www.clinicaltrials.gov/ct2/show/NCT02535091
4. Guignet M, Campbell A, White HS, Epilepsia. 2020 Oct 16. doi: 10.1111/epi.16718. Online ahead of print
5. Nakamura M, et al. Eur J Pharmacol 2019;855:175-182.
6. Sharma R, et al. Eur J Pharmacol 2020;879:173117.
7. https://www.clinicaltrials.gov/ct2/show/NCT03678753
Cautionary Note Regarding Forward-Looking Statements Certain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, the statements by Mr. Di Francesco and any statements relating to regulatory approval or the development, registration, supply, commercialization, distribution or launch of any product. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this press release reflect Endo's current expectations of future events based on existing trends and information and represent Endo's judgment only as of the date of this press release. Actual results may differ materially and adversely from current expectations based on a number of factors affecting Endo's businesses, including, among other things, the following: the outcome of our strategic review, contingency planning and any potential restructuring; the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust matters; actual or contingent liabilities; settlement discussions or negotiations; the impact of competition including loss of exclusivity and generic competition; our ability to satisfy judgments or settlements or to pursue appeals including bonding requirements; our ability to adjust to changing market conditions; our inability to maintain compliance with financial covenants and operating obligations which would expose us to potential events of default under our outstanding indebtedness; our ability to incur additional debt or refinance our outstanding indebtedness; and a significant reduction in our short-term or long-term revenues which could cause us to be unable to fund our operations and liquidity needs. The occurrence or possibility of any such result has caused us to engage, and may result in further engagement, in strategic reviews that ultimately may result in our pursuing one or more significant corporate transactions or other remedial measures, including on a preventative or proactive basis. Those remedial measures could include a potential corporate reorganization, restructuring or bankruptcy filing involving all or a portion of our business, asset sales or other divestitures, cost-saving initiatives, corporate realignments or strategic partnerships. Some of these measures could take significant time to implement and others may require judicial or other third-party approval. Any such actions may be complex, could entail significant costs and charges or could otherwise negatively impact shareholder value, and there can be no assurance that we will be able to accomplish any of these alternatives on terms acceptable to us, or at all, or that they will result in their intended benefits. Therefore, the reader is cautioned not to rely on any forward-looking statements. Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo, as well as Endo's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada , including the discussion under the heading "Risk Factors" in Endo's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S. Securities and Exchange Commission.
View original content: http://www.newswire.ca/en/releases/archive/August2022/08/c7028.html
The FDA offered mixed messages Friday for Amylyx Pharmaceuticals' experimental neurological treatment, and shares crashed.
Ensysce Biosciences Inc (NASDAQ: ENSC) and Quotient Sciences, a drug development and manufacturing accelerator, announced a partnership to support the development and clinical testing of PF614-MPAR. PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain designed to prevent abuse and overdose. Quotient Sciences is currently using its integrated Translational Pharmaceutics platform to identify a PF614-MPAR formulation that allows conversion into oxycodone with
China granted emergency use authorisation to Livzon Pharmaceutical Group Inc's COVID-19 vaccine as a booster, the company said on Friday, one of just two new products against the disease the country has cleared in more than a year. Livzon's vaccine, based on the original coronavirus, if rolled out to the general public would widen booster options for China's 1.4 billion population, of which 90% have been vaccinated and nearly 60% have received a booster dose. The United States has authorised updated COVID-19 booster shots from Pfizer/BioNTech and Moderna that target the BA.4 and BA.5 Omicron subvariants, while countries, including Canada and the UK, also have ordered updated Omicron vaccine boosters for campaigns later this year.
The European Medicines Agency (EMA) on Thursday backed the use of Novavax's COVID-19 shot as a booster for adults, ahead of an anticipated rise in infections this winter. The vaccine, Nuvaxovid, is designed to target the strain of the virus that originally emerged in China. The EMA's recommendation is for people who previously were inoculated with either the Novavax shot, or any other COVID vaccine.
By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT Second Quarter 2022 Operational & Financial Results Alpha Cognition, Inc. (OTC:ACOGF) released 2Q:22 operational and financial results on August 25, 2022 and concurrently filed its annual report with SEDAR. Highlights for 2022 include: ➢ Preclinical histology data for Alpha-1062 in TBI - February 2022 ➢ Preclinical data
Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.
Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky on Thursday signed off on an advisory committee’s recommendation of updated COVID-19 vaccine boosters for people 12 and older, clearing the way for a fall campaign for the shots. Following the CDC’s decision, the vaccinations can now begin. “The updated COVID-19 boosters are formulated to…
Catalyst Pharmaceuticals is now looking for its second act after launching a LEMS treatment. Could CPRX stock investors see a buyout?
Federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, even as they prepare to give its drugmaker a rare second opportunity to make a public case for the treatment. Amylyx Pharmaceuticals' experimental drug has become a rallying cause for patients with the deadly neurodegenerative disease, their families and members of Congress who are pushing the FDA to approve the drug. In March, the same panel of neurological experts voted 6-4 that the company’s data failed to show a convincing benefit for ALS, or amyotrophic lateral sclerosis.
The FDA and CDC have approved new bivalent vaccines by Pfizer and Moderna that target both the original strain of COVID-19 and Omicron subvariants.
Pfizer's updated boosters will be available to patients 12 and up, while Moderna's will be available to patients 18 and older. The FDA greenlit the shots earlier this week.
FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.
Soon after the European Commission's (EC) approval, Sanofi SA (NASDAQ: SNY) scooped up the FDA's OK for the first approved therapy to treat symptoms not related to the central nervous system in patients with acid sphingomyelinase deficiency (ASMD). The indication includes a range of ailments under the umbrella of Niemann-Pick disease. Sanofi now has a rare pediatric disease priority review voucher, making it Sanofi's third PRV. The disease afflicts 1 in every 250,000 people. There are fewer than
BCOR vs. FUTU: Which Stock Is the Better Value Option?
Style Box ETF report for IWX
Our call of the day from RIA Advisors' Micheal Lebowitz says his simple bear market wealth strategy is what investors need right now.
The first part of the merge, dubbed the Bellatrix upgrade, will take place on Sept. 6. And independent researcher and artist Kyle McDonald argues that after the merge, investors and regulators are going to realize that proof-of-work was never really necessary.
Electrification of the roads appears to have tremendous potential not just for Toyota, but for builders, workers, suppliers and governments in the Triad. Toyota’s announcement Wednesday morning that it was more than doubling its investment in its vehicle battery plant at the Greensboro-Randolph Megasite to $3.8 billion from the previously planned $1.29 billion means that much more to go around in Randolph and Guilford counties and surrounding communities. One part of the government incentive package used to lure Toyota in December was a plan for Randolph County to reimburse the company 60% of tax payments over 20 years.
The U.S. dollar is on a tear, hitting historic highs against major rivals. Here's how that could add to market volatility.
Boston Properties Inc. (NYSE: BXP) has sold the office building at 601 Massachusetts Ave. NW for $531 million, according to public records, what will almost certainly be a top sale in the District this year. The buyer, MT D.C. Two LLC, is an affiliate of Tokyo-based Mori Trust Co. Ltd. Executives with Boston Properties declined to comment at this time. The publicly traded developer built the $350 million, 479,000-square-foot office building on the site of the former NPR headquarters after securing a 20-year lease with Arnold & Porter LLP, which occupied its space in late 2015.